Close Menu

UMass

According to the amended complaint, University of Utah's Brenda Bass had “so well-defined” the concept at issue that it "could have been reduced to practice by someone with ordinary skill in the art without further research.”

The funding is worth $250,000 per year for two years and will be matched dollar for dollar by RXi. The award is still subject to a formal agreement between RXi and UMMS.

Life Tech also disclosed that the laboratory of Victor Ambros at the University of Massachusetts Medical School and affiliated RNAi Therapeutics Institute is an early-access customer of the product.

Alnylam said that as part of the agreement, it would allow Merck, the parent company of one-time rival Sirna Therapeutics, to sub-license a portion of the disputed IP to which it previously did not have access.

The company said this week that it has begun manufacturing prototype disposable test cartridges for performing rapid, inexpensive PCR assays as part of a future portable HIV detection and monitoring system for use in developing countries.

While a handful of pricey deals have dominated the headlines, a handful of other companies over the past year have formed more modest collaborations to see whether they can take advantage of RNAi as a therapeutic modality.

The Center for Personalized Cancer Therapy is a joint program with the Dana-Farber/Harvard Cancer Center.

Pages

Researchers in India plan to sequence SARS-CoV-2 isolates from around the country, according to LiveMint.

Mauro Ferrari has resigned as president of the European Research Council over its response to the COVID-19 pandemic, the Financial Times reports.

Stat News reports some health tech startups are laying off or furloughing workers.

In Genome Research this week: indels affecting microsatellites in cancer, analytical approach to find key regulatory elements, and more.